Use Futu NiuNiu to view WUXI XDC (02268)'s stock price, real-time quotes, latest news, historical trend charts, financial information and quotes.
According to the latest financial report of WUXI XDC, the latest earnings per share (TTM) for the company is 0.90. Investing in companies with strong earnings per share can potentially provide higher returns. Currency: HKD Cumulative Quarterly ...
WuXi XDC Cayman Inc + Add to watchlist L74:STU Actions Price (EUR)3.60 Today's Change0.18 / 5.26% Shares traded1.21k 1 Year change+86.53% Beta-- Data delayed at least 15 minutes, as of Feb 04 2025. Find More Stocks Use our equities screener to discover other potential opportunities. ...
Websitehttps://wuxixdc.com/ More ▼ Peer analysis Key Information Key Information Stock Performance Per Share Data Efficiency Management Effectiveness Profitability Financial Strength Growth Rates CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash...
Biotechnology & Medical Research End-of-day quoteShanghai S.E. 2025-04-035-day change1st Jan Change 63.52CNY-3.83% -6.30%+15.41% Apr. 02WuXi AppTec Offloads 4.23% Stake in WuXi XDC CaymanMT Apr. 02WuXi AppTec Announces Disposal Of Certain Share Assets In WuXi XDCRE ...
Hong Kong, Nov. 17, 2023 –WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), congratulates its subsidiary WuXi XDC (stock code: 2268.HK), a leading global Contract Research,
Wuxi Biologics’ share price also increased by around 9 per cent week to date on Apr 11, closing at HK$19.94. As at 11.05am, it was trading higher at HK$21. Morgan Stanley is bullish on the wider Wuxi series, which includes Wuxi Apptech and Wuxi XDC, with an “improving outlook” ...
493 from derivative component of convertible bonds as a result of significant H-share price increase during the Reporting Period. In the first half of 2021, the net gain from venture and fund investments contributed RMB2,148 million, due primarily to fair market value gains post certain ...
Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager,...
Share of Results of Associates Losses from share of results of associates decreased from RMB92.2 million for the year 2021 to RMB52.5 million for the year 2022, primarily due to: (1) increase in equity pick-up gain of RMB81.4 million from WuXi XDC Cayman Inc. and other associates, ...